Presentation is loading. Please wait.

Presentation is loading. Please wait.

Percutaneous Therapy of Pulmonic and Mitral Valve Disease Atman P. Shah MD FACC FSCAI Director, Coronary Care Unit Assistant Professor of Medicine The.

Published byDallin Fann Modified over 9 years ago

Similar presentations

Presentation on theme: "Percutaneous Therapy of Pulmonic and Mitral Valve Disease Atman P. Shah MD FACC FSCAI Director, Coronary Care Unit Assistant Professor of Medicine The."— Presentation transcript:

1 Percutaneous Therapy of Pulmonic and Mitral Valve Disease Atman P. Shah MD FACC FSCAI Director, Coronary Care Unit Assistant Professor of Medicine The University of Chicago February 4th, 2012

2 2 Disclosures Consultant: St. Jude Medical, Abiomed, Medtronic Cardiovascular, Regenerx Speakers Bureau: Astra Zeneca, Medtronic, Novartis NHLBI RO1 HL076671 2

3 Pulmonic Stenosis Stenosis Rheumatic inflammation Supravalvular obstruction Treatment if P-P >50mmHg Size the balloon at 1.25 to annulus Regurgitation Treatment of Tetralogy Congential malformation of valve Associated with VSD, carcinoid, rheumatic involvement, trauma

4 Medtronic Melody Valve 18, 20, 22 mm (28mm) via a 22 French size sheath

5

6

7

8

9 9 Investigational Device only in the US; Not available for sale in the US Perspective >250,000 cases of significant Mitral Regurgitation diagnosed annually in the US Current therapeutic options: –Medical management Effective in symptom management Ineffective in treating underlying pathophysiology or disease progression –Surgical Repair or Replacement (Standard of Care) Effective yet invasive with associated morbidity Only ~20% of patients with significant MR undergo MV surgery Unmet need for an effective less invasive option

10 Investigational Device only in the US; Not available for sale in the US Feldman et al. ACC.10

11

12 Investigational Device only in the US; Not available for sale in the US Feldman et al. ACC.10

13 Investigational Device only in the US; Not available for sale in the US Feldman et al. ACC.10

14 Investigational Device only in the US; Not available for sale in the US Feldman et al. ACC.10

15 15 Investigational Device only in the US; Not available for sale in the US EVEREST II RCT: Patient Flow Post MitraClip Procedure 2 nd MitraClip Procedure n=3 MV Surgery Post MitraClip Procedure n=9 2 nd MitraClip Procedure n=2 No Additional Intervention n=11 MV Surgery Post MitraClip Procedure n=28 Acute Procedural Success Not Achieved n=41 Acute Procedural Success Achieved n=137 n=37 81% Follow-up 96% MR ≤2+ at 12 months

16 Investigational Device only in the US; Not available for sale in the US Feldman et al. ACC.10

17 17 Investigational Device only in the US; Not available for sale in the US Safety Major Adverse Events 30 days Effectiveness Clinical Success Rate * 12 months EII RCT: Safety & Effectiveness Endpoints Intention to Treat Cohort Device Group, n=180 Control Group, n=94 Met superiority hypothesis Pre-specified margin =2% Observed difference = 32.9% 97.5% LCB = 20.7% Control Group, n=89 Device Group, n=175 Met non-inferiority hypothesis Pre-specified margin = 25% Observed difference = 7.3% 95% UCB = 17.8% 66.9% 74.2% 15.0% 47.9% LCB = lower confidence bound UCB = upper confidence bound p SUP <0.0001p NI =0.0005 * Freedom from the combined outcome of death, MV surgery or re-operation for MV dysfunction >90 days post Index procedure, MR >2+ at 12 months

18 Investigational Device only in the US; Not available for sale in the US Feldman et al. ACC.10

19 19 Investigational Device only in the US; Not available for sale in the US Safety & effectiveness endpoints met –Safety: MAE rate at 30 days MitraClip device patients: 9.6% MV surgery patients: 57% –Effectiveness: Clinical Success Rate at 12 months MitraClip device patients: 72% MV Surgery patients: 88% Clinical benefit demonstrated for MitraClip System and MV surgery patients through 12 months Improved LV function Improved NYHA Functional Class Improved Quality of Life Surgery remains an option after the MitraClip procedure EVEREST II RCT: Summary

20

21

22 Conclusions The treatment of pulmonic stenosis involves valvuloplasty with good long term results Emerging technologies allow treatment of valvular disease previously thought to be only operable

Download ppt "Percutaneous Therapy of Pulmonic and Mitral Valve Disease Atman P. Shah MD FACC FSCAI Director, Coronary Care Unit Assistant Professor of Medicine The."

Similar presentations

STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.

STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
ECLIPSE Trial: Ensure’s Vascular Closure Device Speeds Hemostasis S. Chiu Wong MD Director, Cardiac Catheterization Laboratories New York Presbyterian.

ECLIPSE Trial: Ensure’s Vascular Closure Device Speeds Hemostasis S. Chiu Wong MD Director, Cardiac Catheterization Laboratories New York Presbyterian.
Percutaneous mitral valve repair using the MitraClip® device (e-valve)

Percutaneous mitral valve repair using the MitraClip® device (e-valve)
ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.

ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.
IRB PRESENTATION REGULATORY PATHWAYS HDE – PMA William Hellenbrand MD Director – Pediatric Cardiology Columbia University College of Physicians & Surgeons.

IRB PRESENTATION REGULATORY PATHWAYS HDE – PMA William Hellenbrand MD Director – Pediatric Cardiology Columbia University College of Physicians & Surgeons.
Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From.

Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From.
Preliminary results from the C-Pulse OPTIONS HF European Multicenter Post-Market Study Holger Hotz, CardioCentrum Berlin, Berlin, Germany; Antonia Schulz,

Preliminary results from the C-Pulse OPTIONS HF European Multicenter Post-Market Study Holger Hotz, CardioCentrum Berlin, Berlin, Germany; Antonia Schulz,
Valvular Heart Disease. Normal heart valves function to maintain the direction of blood flow through the atria and ventricles to the rest of the body.

Valvular Heart Disease. Normal heart valves function to maintain the direction of blood flow through the atria and ventricles to the rest of the body.
20090417 Few Patients With Functional MR Are Treated Surgically: Duke Database Results Mitchell W. Krucoff MD FACC, FAHA, FSCAI Professor of Medicine /

Few Patients With Functional MR Are Treated Surgically: Duke Database Results Mitchell W. Krucoff MD FACC, FAHA, FSCAI Professor of Medicine /
TAVR Pearls Addressing the Shortcomings of the Current TAVR Generation

TAVR Pearls Addressing the Shortcomings of the Current TAVR Generation
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.

Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
Impact of Concomitant Tricuspid Annuloplasty on Tricuspid Regurgitation Right Ventricular Function and Pulmonary Artery Hypertension After Degenerative.

Impact of Concomitant Tricuspid Annuloplasty on Tricuspid Regurgitation Right Ventricular Function and Pulmonary Artery Hypertension After Degenerative.
Blood Pressure Lability During Cardiac Surgery Is Associated With Adverse Outcomes Solomon Aronson, Edwin G. Avery, Cornelius Dyke, Joseph Varon, Jerrold.

Blood Pressure Lability During Cardiac Surgery Is Associated With Adverse Outcomes Solomon Aronson, Edwin G. Avery, Cornelius Dyke, Joseph Varon, Jerrold.
Percutaneous Repair or Surgery for Mitral Regurgitation EVEREST II Objective:to compare the efficacy of percutaneous implantation of a clip and conventional.

Percutaneous Repair or Surgery for Mitral Regurgitation EVEREST II Objective:to compare the efficacy of percutaneous implantation of a clip and conventional.
1 Investigational Device only in the U.S. Not available for sale in the U.S. ACCESS EU – ESC 2012 European Society of Cardiology Congress 2012 Munich,

1 Investigational Device only in the U.S. Not available for sale in the U.S. ACCESS EU – ESC 2012 European Society of Cardiology Congress 2012 Munich,
©2015 MFMER | 3428638-1 Robotic Repair of Simple vs. Complex Degenerative Mitral Valve Disease Clinical and Echocardiographic Outcomes During Mid-Term.

©2015 MFMER | Robotic Repair of Simple vs. Complex Degenerative Mitral Valve Disease Clinical and Echocardiographic Outcomes During Mid-Term.
Randomized Trial of Ea rly S urgery Versus Conventional Treatment for Infective E ndocarditis (EASE) Duk-Hyun Kang, MD, PhD on behalf of The EASE Trial.

Randomized Trial of Ea rly S urgery Versus Conventional Treatment for Infective E ndocarditis (EASE) Duk-Hyun Kang, MD, PhD on behalf of The EASE Trial.
Surgical outcome of native valve infective endocarditis in srinagarind hospital 2004-2005.

Surgical outcome of native valve infective endocarditis in srinagarind hospital
Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III.

Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III.
Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis David H. Adams et al (U.S. CoreValve Clinical Investigators) Journal Club November.

Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis David H. Adams et al (U.S. CoreValve Clinical Investigators) Journal Club November.

Similar presentations

Ads by Google